Wedbush Reiterates Outperform on Omega Therapeutics, Maintains $12 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Omega Therapeutics (NASDAQ:OMGA) and maintained a $12 price target.
August 07, 2024 | 2:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Omega Therapeutics (NASDAQ:OMGA) and maintained a $12 price target.
The reiteration of an Outperform rating and the maintenance of a $12 price target by a reputable analyst can boost investor confidence in Omega Therapeutics, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100